1. |
European Medicines Agency. Assessment Report. Procedure UnderArticle 31 of Directive 2001/83/EC Resulting from PharmacovigilanceData. 2014. Available at:http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Valproate_and_related_substances_31/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500177352.pdf. Accessed April, 2015.
|
2. |
Nau H. Teratogenic valproic acid concentrations:infusion byimplanted minipumps vs conventional injection regimen in the mouse.Toxicol Appl Pharmacol, 1985, 80(12):243-250.
|
3. |
Mawhinney E, Campbell J, Craig J, et al. Valproate and the risk of congenitalmalformations:is formulation and dosage regime important?.Seizure, 2012, 21(3):215-218.
|
4. |
Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk ofmalformations with antiepileptic drugs:an analysis of data from theEURAP epilepsy and pregnancy registry. Lancet Neurol, 2011, 86(10):609-617.
|
5. |
Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drugexposure and cognitive outcomes at age 6 years (NEAD study):a prospectiveobservational study. Lancet Neurol, 2013, 12(8):244-252.
|
6. |
Meador K, Reynolds MW, Crean S, et al. Pregnancy outcomes inwomen with epilepsy:a systematic review and meta-analysis of publishedpregnancy registries and cohorts. Epilepsy Res, 2008, 81(2):1-13.
|
7. |
Hernandez-Diaz S, Smith CR, Shen A, et al. Comparative safety of antiepilepticdrugs during pregnancy. Neurology, 2012, 78(12):1692-1699.
|
8. |
Campbell E, Kennedy F, Russell A, et al. Malformation risks of antiepilepticdrug monotherapies in pregnancy:updated results from the UKand Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry, 2014, 85(5):1029-1034.
|
9. |
Veiby G, Daltveit AK, Engelsen BA, et al. Fetal growth restrictionand birth defects with newer and older antiepileptic drugs duringpregnancy. J Neurol, 2014, 261(11):579-588.
|
10. |
Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Lancet Neurol, 2012, 11(3):803-813.
|
11. |
Mawhinney E, Craig J, Morrow J, et al. Levetiracetam in pregnancy:results from the UK and Ireland epilepsy and pregnancy registers. Neurology, 2013, 80(5):400-405.
|
12. |
Hunt S, Russell A, Smithson WH, et al. UK Epilepsy and PregnancyRegister. Topiramate in pregnancy:preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology, 2008, 71(11):272-276.
|
13. |
Samr'en EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations:a joint European prospective study of human teratogenesis associated with maternal epilepsy.Epilepsia, 1997, 38(10):981-990.
|
14. |
Samr'en EB, van Duijn CM, Christiaens GC, et al. Antiepileptic drugregimens and major congenital abnormalities in the offspring. Ann Neurol, 1999, 46(9):739-746.
|
15. |
Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res, 1999, 33(8):145-158.
|
16. |
Artama M, Auvinen A, Raudaskoski T, et al. Antiepileptic drug use ofwomen with epilepsy and congenital malformations in offspring. Neurology, 2005, 64(8):1874-1878.
|
17. |
Bromley R, Weston J, Adab N, et al. Treatment for epilepsy in pregnancy:neurodevelopmental outcomes in the child. Cochrane Database Syst Rev, 2014, Art. No:CD010236.
|
18. |
Baker GA, Bromley RL, Briggs M, et al. IQ at 6 years following inutero exposure to antiepileptic drugs:a controlled cohort study. Neurology, 2015, 84(2):382-390.
|
19. |
Shallcross R, Bromey RL, Cheyne CP, et al. In utero exposure to levetiracetamvs valproate. Neurology, 2014, 82(6):213-221.
|
20. |
Cohen MJ, Meador KJ, Browning N, et al. Fetal antiepileptic drugexposure:motor, adaptive, and emotional/behavioral functioning a tage 3 years. Epilepsy Behav, 2011, 22(9):240-246.
|
21. |
Cohen MJ, Meador KJ, Browning N, et al. Fetal antiepileptic drug exposure:adaptive and emotional/behavioral functioning at age 6 years. Epilepsy Behav, 2013, 29(8):308-315.
|
22. |
Christensen J, Gronborg TK, Sorensen MJ, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism.JAMA, 2013, 309(21):1696-1703.
|
23. |
Posner EB, Mohamed KK, Marson AG. Ethosuximide, sodium valproateor lamotrigine for absence seizures in children and adolescents.Cochrane Database Syst Rev, 2005, Art. No:CD003032.
|
24. |
Coppola G, Auricchio G, Federico R, et al. Lamotrigine versus valproicacid as first-line monotherapy in newly diagnosed typical absence seizures:an open-label, randomized, parallel-group study. Epilepsia, 2004, 45(11):1049-1053.
|
25. |
Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acidand lamotrigine in childhood absence epilepsy. N Engl J Med, 2010, 362(31):790-799.
|
26. |
Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalized and unclassifiable epilepsy:an unblended randomised controlled trial.Lancet, 2007, 369(10):1016-1026.
|
27. |
Bonnett LJ, Tudur Smith C, et al. Time to 12-month remission and treatment failure for generalised and unclassified epilepsy. J Neurol Neurosurg Psychiatry, 2014, 85(2):603-610.
|
28. |
Fattore C, Boniver C, Capovilla G, et al. A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. Epilepsia, 2011, 52(12):802-809.
|
29. |
Marson AG, Williamson PR, Hutton JL, et al. Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database Syst Rev, 2000, Art. No:CD001030.
|
30. |
Nolan SJ, Marson AG, Pulman J, et al. Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonicseizures. Cochrane Database Syst Rev, 2013, Art. No:CD001769.
|
31. |
Tudur Smith C, Marson AG, Chadwick DW, et al. Multiple treatment comparisons in epilepsy monotherapy trials. Trials, 2007, 8(1):34.
|
32. |
Trinka E, Marson AG, Van Paesschen W, et al. KOMET:anunblinded, randomised, two parallel-group, stratified trial comparingthe effectiveness of levetiracetam with controlled-release carbamazepineand extended-release sodium valproate as monotherapy in patientswith newly diagnosed epilepsy. J Neurol Neurosurg Psychiatry, 2013, 84(8):1138-1147.
|
33. |
Park KM, Kim SH, Nho SK, et al. A randomized open-label observational study to compare the efficacy and tolerability between topiramate and valproate in juvenile myoclonic epilepsy. J Clin Neurosci, 2013, 20(6):1079-1082.
|
34. |
Levisohn PM, Holland KD. Topiramate or valproate in patients with juvenile myoclonic epilepsy:a randomized open-label comparison.Epilepsy Behav, 2013, 52(11):1150-1159.
|
35. |
Noachtar S, Andermann E, Meyvisch P, et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures.Neurology, 2008, 70(12):607-616.
|
36. |
Covanis A, Gupta AK, Jeavons PM. Sodium valproate:monotherapy and polytherapy. Epilepsia, 1982, 23(8):693-720.
|
37. |
Bourgeois B, Beaumanoir A, Blajev B, et al. Monotherapy with valproatein primary generalized epilepsies. Epilepsia, 1987, 28 (Suppl. 2):8-11.
|
38. |
Nicolson A, Appleton RE, Chadwick DW, et al. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry, 2004, 75(3):75-79.
|
39. |
Genton P. When antiepileptic drugs aggravate epilepsy. Brain Dev, 2000, 22(4):75-80.
|
40. |
Hesdorffer DC, Tomson T, Benn E, et al. Combined analysis of risk factors for SUDEP. Epilepsia, 2011, 52(10):1150-1159.
|
41. |
Nilsson L, Tomson T, Farahmand BY, et al. Cause-specific mortalityin epilepsy:a cohort study of more than 9000 patients once hospitalized for epilepsy. Epilepsia, 1997, 38(8):1062-1068.
|
42. |
Tomson T, Beghi E, Sundqvist A, et al. Medical risks in epilepsy:a review with focus on physical injuries, mortality, traffic accidents and their prevention. Epilepsy Res, 2004, 60(7):1-16.
|
43. |
Granbichler CA, Oberaigner W, Kuchukhidze G, et al. Cause-specific mortality in adult epilepsy patients from tyrol, Austria:hospital-basedstudy. J Neurol, 2015, 262(3):126-133.
|
44. |
Trinka E, Bauer G, Oberaigner W, et al. Cause-specific mortality among patients with epilepsy:results from a 30-year cohort study. Epilepsia, 2013, 54:495-501.
|
45. |
Cummings C, Stewart M, Stevenson M, et al. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine.Arch Dis Child, 2011, 96(7):643-647.
|
46. |
Grosso S, Balestri M, Di Bartolo RM, et al. Oxcarbazepine and atypical evolution of benign idiopathic focal epilepsy of childhood. Eur J Neurol, 2006, 13(6):1142-1145.
|
47. |
Wheless JW, Clarke DF, Arzimanoglou A, et al. Treatment of pediatric epilepsy:European expert opinion, 2007. Epileptic Disord, 2007, 9(2):353-412.
|
48. |
Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies:report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia, 2010, 51(9):676-685.
|
49. |
Callenbach PM, Bouma PA, Geerts AT, et al. Long-term outcome of childhood absence epilepsy:Dutch study of epilepsy in childhood.Epilepsy Res, 2009, 83(7):249-256.
|
50. |
Trinka E, Baumgartner S, Unterberger I, et al. Long-term prognosis for childhood and juvenile absence epilepsy. J Neurol, 2004, 251(17):1235-1241.
|
51. |
Covanis A, Skiadas K, Loli N, et al. Absence epilepsy:early prognostic signs. Seizure, 1992, 1(3):281-289.
|
52. |
Caraballo RH, Flesler S, Pasteris MC, et al. Myoclonic epilepsy in infancy:an electro clinical study and long-term follow-up of 38patients. Epilepsia, 2013, 54(20):1605-1612.
|
53. |
Wallace S. Myoclonus and epilepsy in childhood:a review of treatment with Valproate, Ethosuximide, Lamotrigine and Zonisamide. Epilepsy Res, 1998, 29(10):147-154.
|
54. |
Genton P, Bureau M. Epilepsy with myoclonic absences. CNS Drugs, 2006, 20(8):911-916.
|
55. |
Oguni H, Tanaka T, Hayashi K. Treatment and long-term prognosis of myoclonic-astatic epilepsy of early childhood. Neuro pediatrics, 2002, 33(8):122-132.
|
56. |
Liukkonen E, Kantola-Sorsa E, Paetau R, et al. Long-term outcome of 32 children with encephalopathy with status epilepticus during sleep, or ESES syndrome. Epilepsia, 2010, 51(8):2023-2032.
|
57. |
Shahwan A, Farrell M, Delanty N. Progressive myoclonic epilepsies:a review of genetic and therapeutic aspects. Lancet Neurol, 2005, 4(1):239-248.
|
58. |
Avula S, Parikh S, Demarest S, et al. Treatment of mitochondrial disorders.Curr Treat Options Neurol, 2014, 16(7):292.
|
59. |
Chiron C, Dulac O. The pharmacologic treatment of dravet syndrome.Epilepsia, 2011, 52 (Suppl. 2):72-75.
|
60. |
Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy:a randomised placebo-controlled syndrome dedicated trial. STICLO study group. Lancet, 2000, 356(11):1638-1642.
|
61. |
Trinka E, Dilitz E, Unterberger I, et al. Non convulsive status epilepticus after replacement of valproate with lamotrigine. J Neurol, 2002, 249(10):1417-1422.
|
62. |
MRC Antiepileptic Drug Withdrawal Study Group. Randomised study of antiepileptic drug withdrawal in patients in remission. Lancet, 1991, 337(8):1175-1180.
|
63. |
MRC Antiepileptic Drug Withdrawal Study Group. Prognostic indexfor recurrence of seizures after remission of epilepsy. BMJ, 1993, 306(10):1374-1378.
|